TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01629979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Grafting with epidermal cells
Description: A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments.
Study: NCT02589197

Intervention type: DEVICE
Intervention: Group 2 (Posterior-Stabilized)
Description: Zimmer® NexGen® Total Knee Arthroplasty system with PS inserts
Study: NCT03247582

Intervention type: DRUG
Intervention: Edoxaban
Description: Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
Study: NCT02352779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03178032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNX-2401
Description: Brain infusion of the virus through the cerebellar peduncle
Study: NCT03970928

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: A pulse oximetry probe which transfers data to the monitor with software able to calculate PVI data. The monitor automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor.
Study: NCT03692390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
Study: NCT01957176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag (ELT)
Description: Subjects were dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets were white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS was a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet contained ELT olamine equivalent to 20 mg of ELT per gram of powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag (ELT)
Description: Subjects were dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets were white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS was a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet contained ELT olamine equivalent to 20 mg of ELT per gram of powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag (ELT)
Description: Subjects were dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets were white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS was a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet contained ELT olamine equivalent to 20 mg of ELT per gram of powder.
Study: NCT00336245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copper T Intrauterine Contraceptive Device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormonal Contraception
Study: NCT01841476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6326
Study: NCT04053920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Load Resistance exercise
Description: leg extension, leg press, leg curl and calf press

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Load Resistance exercise
Description: leg extension, leg press, leg curl and calf press
Study: NCT01167322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-07 for oral administration
Description: NPC-07, containing 1.5g of 5-aminolevulinic acid hydrochloride per vial, is dissolved in 50 mL of water and will be administered orally 3 hours (range 2-4 hours) prior to induction of anesthesia at a dose of 20mg/kg body weight.
Study: NCT00291980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-AS02V vaccine
Description: HB-AS02V (20µg HBsAg) will be administered at Month 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBVAXPRO vaccine
Description: HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0
Study: NCT03822065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005
Description: 80 mg oral tablet single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005
Description: 80 mg oral tablet single dose
Study: NCT01195792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1521498
Description: GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1521498
Description: GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given for up to 35 days and subjects will be assessed weekly
Study: NCT03282630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion acupuncture
Description: * active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process~* sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sphenopalatine ganglion acupuncture
Description: * active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process~* sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
Study: NCT01629979

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB treatment
Description: the control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments.
Study: NCT01228188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inverted ILM Repositioning
Description: Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. First a 0.6-1.0mm piece of ILM surrounding the macular hole is removed. Then significant margin of ILM in macular hole circumference is released while staying connected at the base to the macularrhexis border. Excess of ILM is trimmed. Perfluorocarbon is administrated, stabilizing ILM flap and facilitating the flap repositioning. Trypan Blue is used to stain the ILM. ILM flap is pressed down over the macular hole. The procedure is ended by SF6 gas tamponade. Even in absence of cataract formation, a combined procedure is performed because of exact peripheral vitreous shaving and prevention of cataract formation.
Study: NCT04042012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: soleus eccentric exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNE
Description: the application of galvanic current

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined
Description: soleus eccentric exercise and PNE
Study: NCT00498225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus TS-1
Description: Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1
Description: TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.
Study: NCT02088541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor oral tablet.
Study: NCT03345901

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally BID - twice daily
Study: NCT02088541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor oral tablet.
Study: NCT04209712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haploid allogeneic NK cell therapy
Description: NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.
Study: NCT00722046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 0.1 mg/kg
Description: 0.1 mg/kg every 60 days (10 doses total)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 0.5 mg/kg
Description: 0.5 mg/kg every 60 days (10 doses total)
Study: NCT02088541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C
Description: Ara-C Subcutaneous Injection.
Study: NCT00722046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 1 mg/kg
Description: 1 mg/kg every 60 days (10 doses total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every 60 days (10 doses total)
Study: NCT03674086

Intervention type: DEVICE
Intervention: eAdjust 0.2 hearing aid smartphone application (or app)
Description: The app connects to the Audeo B-90 Direct hearing aids via Bluetooth. The intended use for the app to enable hearing aid users to fine-tune their hearing aids. The app contains a series of sound modifiers, factory presets, sound modifier presets.

Intervention type: DEVICE
Intervention: eAdjust 0.2 hearing aid smartphone application (or app)
Description: The app connects to the Audeo B-90 Direct hearing aids via Bluetooth. The intended use for the app to enable hearing aid users to fine-tune their hearing aids. The app contains a series of sound modifiers, factory presets, sound modifier presets.
Study: NCT00440544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT6 fusion protein H1
Description: 100 ug H1 antigen in BCG naive subjects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT6 fusion protein H1
Description: 100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT6 fusion protein H1
Description: 50 ug H1 antigen in BCG immunized subjects
Study: NCT02533778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical thrombectomy
Description: Mechanical thrombectomy by either Penumbra system, TREVO, or Solitaire retrieval device
Study: NCT04397796

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-Allo.MSC
Description: BM-Allo.MSC for Infusion, is manufactured from normal donor derived bone marrow product and are phenotypically CD73+, CD90+, CD105+, and negative for CD14-, CD34-, CD45-, HLA-DR-.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: plasmalyte and human albumin
Study: NCT02015806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RxTimerCap
Description: The RxTimerCap is a pill bottle cap with a digital timer that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RxTimerCap
Description: The RxTimerCap is a pill bottle cap with a digital timer that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RxTimerCap
Description: The RxTimerCap is a pill bottle cap with a digital timer that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RxTimerCap
Description: The RxTimerCap is a pill bottle cap with a digital timer that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
Study: NCT00440544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT6 fusion protein H1
Description: 50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT6 fusion protein H1
Description: 100 ug H1 antigen in BCG immunized subjects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT6 fusion protein H1
Description: 100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
Study: NCT03222583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Coformulated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Coformulated tablet for oral administration
Study: NCT00722046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 3 mg/kg
Description: 3 mg/kg every 60 days (10 doses total)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 8.5 mg/kg
Description: 8.5 mg/kg every 60 days (10 doses total)
Study: NCT00402896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: 300 mg/day orally for 10 weeks.
Study: NCT04048044

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to GHz electromagnetic energy (RejuvaMatrix)
Description: 75 decibels of 54 to 78 GHz daily for 60 minutes
Study: NCT03239912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin-block appliance
Description: Functional treatment will be achieved using the Twin-block appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin-block appliance
Description: Functional treatment will be achieved using the Twin-block appliance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser
Description: Functional treatment will be combined with low-level laser therapy on the TMG region
Study: NCT02015806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take-N-Slide
Description: The Take-N-Slide device is a patented strip with toggles for each day of the week which are meant to be slid after taking a medication. Each Take-N-Slide can be removed and reused for the next prescription bottle. Patients randomized to receive Take-N-Slide will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
Study: NCT03039244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser
Study: NCT02015806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take-N-Slide
Description: The Take-N-Slide device is a patented strip with toggles for each day of the week which are meant to be slid after taking a medication. Each Take-N-Slide can be removed and reused for the next prescription bottle. Patients randomized to receive Take-N-Slide will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillbox
Description: The standard pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillbox
Description: The standard pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillbox
Description: The standard pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillbox
Description: The standard pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.